risk factors
The absolute risk depends on tumor type, stage of disease, administration of chemotherapy and/or hormone therapy, surgical intervention, the presence of an indwelling central venous catheter, age, immobilization and previous history of VTE. Pre-chemotherapy platelet count of ‡350 · 10 9 /l, use of erythropoiesis-stimulating agents, leukocyte count >11 · 10 9 /l and body mass index of ‡35 kg/m 2 are associated with an increased risk of developing VTE in ambulatory cancer patients. The role of hereditary thrombophilia is still unclear. Screening for the most common polymorphisms is therefore not indicated.
diagnosis of VTE in occult malignancy
There is general agreement that patients with idiopathic thrombosis present a higher risk of occult cancer. Part of these malignancies can be identified by routine assessments at the time of the thrombotic event. To date, without definitive data to demonstrate an advantage in terms of overall survival using invasive diagnostic tests and intensive follow-up, patients should undergo only physical examination, occult fecal blood test, chest X-ray, urological visit in men, gynecological visit in . dalteparin) or 100 U/kg (100 units of anti-Xa activity per kg of body weight) administered twice daily (e.g. enoxaparin) or UFH intravenously (i.v.) in continuous infusion. UFH is first administered as a bolus of 5000 IU, followed by continuous infusion, nearly 30 000 IU over 24 h, adjusted to achieve and maintain an activated partial thromboplastin time (aPTT) prolongation of 1.5-2.5 times the basal value. In patients with severe renal failure (creatinine clearance <25-30 ml) UFH i.v. or LMWH with anti-Xa activity monitoring is recommended [I, A].
acute treatment: thrombolytic therapy
Thrombolytic treatment should be considered for specific subgroups of patients such as those with pulmonary embolism presenting with severe right ventricular dysfunction, and for patients with massive ilio-femoral thrombosis at risk for limb gangrene, where rapid venous decompression and flow restoration may be desirable. Urokinase, streptokinase and tissue-type plasminogen activator are able to achieve a rapid lysis of fresh pulmonary emboli [II, A].
Long-term treatment. According to standard treatment, the initial phase is followed by treatment with oral anticoagulation with vitamin K antagonists (VKAs) administered for 3-6 months, at a therapeutic INR range of 2-3. VKAs are started within 24 h of initiation of heparin (UFH or LMWH) administration. A full dose of heparin is continued for at least 5 days and suspended when full anticoagulation by VKA (i.e. INR > 2.0) is achieved for at least 2 consecutive days.
However, oral anticoagulation with VKA may be problematic in patients with cancer. Drug interactions, malnutrition and liver dysfunction can lead to wide fluctuations in INR. Cancer patients have both a higher rate of VTE recurrences during oral anticoagulant therapy with VKA and a higher anticoagulationassociated hemorrhagic risk as compared with non-cancer patients.
Results from recent randomized clinical trials demonstrate that in these patients long-term treatment for 6 months with 75-80% (i.e. 150 U/kg o.d.) of the initial dose of LMWH is safe and more effective than treatment with VKAs. This schedule is recommended for long-term anticoagulant therapy in cancer patients [ 
